Refine by
Fatty Liver Disease Articles & Analysis
19 news found
Such fat accumulation can have serious health consequences, raising the risk of chronic diseases like cardiovascular conditions, diabetes, and some cancers. It is usually associated with a higher prevalence of non-alcoholic fatty liver disease (NAFLD) and asthma. ...
This service intuitively studies the relationship between gut flora and disease development, providing new ideas for disease prevention and treatment and improving host health. ...
In the first two Part B cohorts, ALN-HSD was associated with robust target knockdown and numerically lower liver enzymes and biopsy-derived nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS)* over six months in patients receiving ALN-HSD (N=20) relative to placebo (N=4). ...
This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the most common biomarker used for HCC detection today. ...
Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD,” commented Rick Hawkins, CEO and Chairman of Lumos Pharma. “Nonalcoholic fatty liver disease is estimated to be prevalent in approximately 25% of adults worldwide. ...
The Company also today announced the completion of enrollment in its 12-week Phase 1b clinical trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). The 48-week MOMENTUM trial is being conducted at approximately 25 sites in the United States with Dr. ...
“Their support is based on the recognition that fatty liver disease is a significant health issue and underscores the need for an accurate, accessible and affordable point of care tool to assess patients affected by this often-silent ...
In addition, Nature Scientific Reports published the company’s research analyzing gene expression at various stages of nonalcoholic fatty liver disease. NASH, one of the leading causes of transplantation, is a serious, chronic liver disease that is estimated to impact over 16 million people in the United ...
When measuring fatty liver disease in obese patients, a greater imaging depth (below subcutaneous fat and the liver capsule) results in a more accurate liver health assessment. ...
It is this imbalance, which came to the attention of Fractyl Health’s founders, that then led to the company’s pursuit of therapeutic approaches that can potentially correct the hormonal signals from the intestine and stem the tide of metabolic diseases in society. “Within the past three months, we have seen several publications from leading scientists that are ...
With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. ...
DMR Treatment Revita DMR is based on Fractyl’s breakthrough insights surrounding the role of the gut in metabolic diseases. An outpatient endoscopic procedure, Revita DMR resurfaces the lining of the upper intestine (duodenal mucosa). ...
The product, a non-invasive neurostimulation device using gamma frequency technology, is the first in the company’s pipeline of digital therapeutics for neurodegenerative diseases and other chronic indications. The company also released results from two clinical studies at the Alzheimer’s Disease Parkinson’s Disease Conference ...
“It’s a great honour to be recognized by Rocket Builders for the second year in a row,” said George Aliphtiras, CEO, Sonic Incytes Medical Corp. “Fatty liver disease is an emerging health crisis that affects 1 in 4 people worldwide and, with FDA clearance of VelacurTM, we’re excited to offer health care practitioners ...
(Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. ...
“Eliminating the need for daily insulin could transform disease management for the hundreds of millions of people across the world suffering from type 2 diabetes. ...
” “Fractyl's founding mission was to find a better way to treat type 2 diabetes by addressing the root cause of disease that can reverse the disease process rather than manage its symptoms. ...
This minimally-invasive, outpatient, endoscopic procedure is a non-drug and non-surgical alternative that has been shown in clinical trials to enhance insulin sensitivity, lower HbA1c, and reduce liver fat to create long-lasting improvements in both blood sugar control and fatty liver disease to help patients with type 2 diabetes ...
Non-Alcoholic Steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD). The global prevalence of NAFLD is as high as one billion and is the most common cause of chronic liver disease, affecting between 80 and 100 million in the U.S., among whom nearly 25% progress to NASH. NASH ...